Table 3 Summary of patient characteristics for each antimalarial drug

Median of mean age (years)

25.6

26

26

23.4

19.9

20.8

–

22.1

33

% missing data for mean age

55

80

64

38

41

71

93

60

57

Median of median age (years)

16.4

24

25

23

23.8

–

–

–

–

% missing data for median age

93

96

85

88

91

94

100

100

100

Age range (years)

0.3–90

0.4–88

0.2–75

6–65

0.25–84

1–74

12–62

0.8–65

16–74

Total number of males

2571

5137

5226

4522

684

1052

723

287

373

Total number of females

1141

1848

4233

2682

256

422

377

519

118

% (number) trials including healthy participants

14 (7)

22 (10)

28 (11)

29 (7)

18 (4)

35 (6)

14 (2)

40 (4)

71 (5)

% (number) trials including P. falciparum infection

88 (45)

78 (35)

72 (28)

71 (17)

77 (17)

41 (7)

86 (12)

60

14 (1)

% (number) trials including P. vivax infection

4 (2)

0 (0)

5 (2)

17 (4)

14 (3)

29 (5)

7 (1)

0 (0)

14 (1)

% (number) trials including uncomplicated malariainfection

45 (23)

69 (31)

72 (28)

71 (17)

77 (17)

35 (6)

71 (10)

60 (6)

29 (2)

% (number) trials including complicated or severe malaria infection

51 (26)

4 (2) (both studies also trialled quinine)

0 (0)

0 (0)

0 (0)

12 (2) (1 study just chloroquine, the other also trialled quinine)

0 (0)

0 (0)

0 (0)

% (number) trials excluding any medical comorbidities

31 (16)

58 (26)

62 (24)

71 (17)

68 (15)

65 (11)

57 (8)

90 (9)

86 (6)

% (number) trials specifically excluding cardiovascular comorbidities

12 (6)

16 (7)

49 (19)

38 (9)

46 (10)

41 (7)

14 (2)

60 (6)

57 (4)

% (number) trials excluding any co-medication use

65 (33)

53 (24)

62 (24)

42 (10)

54 (12)

71 (12)

57 (8)

100 (10)

86 (6)

% (number) trials excluding co-medication with antimalarials

57 (29)

44 (20)

39 (15)

13 (3)

36 (8)

24 (4)

50 (7)

80 (8)

43 (3)

% (number) trials excluding drugs which interfere with cardiovascular system

6 (3)

2 (1)

23 (9)

13 (3)

18 (4)

12 (2)

0 (0)

30 (3)

0 (0)